BioCentury
ARTICLE | Clinical News

LPCN 1021: Completed Phase III enrollment

May 12, 2014 7:00 AM UTC

Lipocine completed enrollment of 315 patients with low testosterone (<300 ng/dL) in the open-label, U.S. Phase III SOAR trial comparing twice-daily oral LPCN 1021 vs. once-daily AndroGel 1.62% testos...